Secretion of tumour necrosis factor α and lymphotoxin α in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease

Scandinavian Journal of Immunology

Volumn 43, Issue 4, 1996, Pages 456-463

  Bouma, G ^a   Crusius, J B A ^a   Oudkerk Pool, M ^d   Kolkman, J J ^a   Von Blomberg, B M E ^a   Kostense, P J ^b   Giphart, M J ^c   Schreuder, G M Th ^c   Meuwissen, S G M ^a   Pena A S ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d HOSPITAL DE WEEZENLANDEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DR ANTIGEN; LYMPHOTOXIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENTERITIS; ETIOLOGY; FEMALE; GENETIC POLYMORPHISM; HAPLOTYPE; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; PRIORITY JOURNAL;

EID: 9244244710     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1996.d01-65.x     Document Type: Article

References (40)

1. Freidel AC, Betuel H, Gebuhrer L, Farre A, Lambert J. Cellular and serological subtypes of HLA-DR2. Tissue Antigens 1987;29:129-40.
2. Toyoda H, Wang SJ, Yang HY et al. Distinct associations of HLA class II genes with inflammatory bowel disease. Gastroenterology 1993;104:741-8.
3. Sugimura K, Asakura H, Mizuki M et al. Analysis of genes within the HLA region affecting susceptibility to Ulcerative Colitis. Hum Immunol 1993;36:112-18.
4. Masuda H, Nakamura Y, Tanaka T, Hayakawa S. Distinct relationship between HLA-DR genes and intractability of ulcerative colitis. Am J Gastroenterol 1994; 89: 1957-62.
5. Futami S, Aoyama N, Honsako Y et al. HLA-DRB1*1502 allele, subtype of DR15, is associated with susceptibility to ulceralive colitis and its progression. Dig Dis Sci 1995;40:814-18.
6. Jacob CO. Tumour necrosis factor alpha in autoimmunity: pretty girl or old witch? Immunol Today 1992;13:122-5.
7. Jacob CO, Fronek Z, Lewis GD, Koo M, Hansen JA, McDevitt HO. Heritable major histocompatibility complex class II-associated differences in production of tumour necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci USA 1990;87:1233-7.
8. K Messer G, Spengler U, Jung MC et al. Polymorphic structure of the tumour necrosis factor (TNF) locus: a Ncol polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J Exp Med 1991;173:209-19.
9. Pociot F, Molvig J, Wogensen L et al. A tumour necrosis factor beta gene polymorphism in relation to monokine secretion and insulin-dependent diabetes mellitus. Scand J Immunol 1991;33: 37-49.
10. Pociot F, Briant L, Jongeneel CV et al. Association of tumour necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-alpha by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus. Eur J Immunol 1993;23:224-31.
11. Ferencik S, Lindemann M, Horsthemke B, Grosse-Wilde H. A new restriction fragment length polymorphism of the human TNF-beta gene detected by AspHI digest. Eur J Immunogenetics 1992;19:425-30.
12. Wilson AG, di Giovine FS, Blakemore AIF, Duff GW. Single base polymorphism in the human Tumour Necrosis Factor (TNF) alpha gene detectable by NcoI restriction of PCR product. Hum Mol Gen 1992;1:353.
13. Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LBA, Duff GW. An allelic polymorphism within the human tumour necrosis factor alpha promoter region is strongly associ-ated with HLA A1, B8, and DR3 alleles. J Exp Med 1993; 177:557-60.
14. D'Alfonso S, Momigliano Richiardi P. A polymorphic variation in a putative regulation box of the TNFA promoter region. Immunogenetics 1994;39:150-4.
15. Crusius JBA, Bing X, Mulder CJJ, Mearin ML, Peña AS. Relevance of haplotypes in the TNF region in celiac disease. Eur Cytokine Netw 1994;5:168A.
16. Bouma G, Oudkerk Pool M, Scharenberg JGM et al. Differences in the intrinsic capacity of T-cells to produce the cytokines tumour necrosis factor alpha and beta in patients with inflammatory bowel disease and healthy controls. Scand J Gastroenterol 1995;30:1095-100.
17. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 170 1989;24:2-6.
18. Sutherland LR, Martin F, Greer S et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987;92:1894-8.
19. Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's disease activity index. Gastroenterology 1979;77:843-6.
20. Verduyn W, Doxiadis UN, Anholts J et al. Biotinylated DRB sequence-specific oligonucleotides. Comparison to serologic HLA-DR typing of organ donors in Eurotransplant. Hum Immunol 1993;37:59-67.
21. Mehra NK, Verduyn W, Taneja V, Drabbels J, Singh SPN, Giphart MJ. Analysis of HLA-DR2-associated polymorphisms by oligonucleotide hybridization in an Asian Indian population. Hum Immunol 1991;32:246-53.
22. Zier K, Gansbacher B, Salvadori S. Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy. Immunology Today 1996;17:39-45.
23. Dixon WJ. BMDP Statistical Software Manual. Berkeley: University of California Press, 1992.
24. Bouma G, Xia B, Crusius JBA et al. Distribution of four polymorphisms in the tumour necrosis factor genes in patients with inflammatory bowel disease. Clin Exp Immunol 1996;103:391-6.
25. McGuire W, Hill ASV, Allsop CEM, Greenwood BM, Kwiatkowski D. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature 1994;371: 508-11.
26. Cabrera M, Shaw MA, Sharpies C et al. Polymorphism in tumour necrosis factor genes associated with mucocutaneous leishmaniasis. J Exp Med 1995;182:1259-64.
27. Wilson AG, Symons JA, McDowell TL, di Giovine FS, Duff GW. Effects of a tumour necrosis factor (TNF-alpha) promoter base transition on transcriptional activity. Br J Rheumatol 1994;33:89A.
28. Brinkman BMN, Zuijdgeest D, Kaijzel EL et al. Functional consequences of the TNFα -308 polymorphism on gene expression. Immunology 1995;86:75A.
29. Abraham LJ, French MAH, Dawkins RL. Polymorphic MHC ancestral haplotypes affect the activity of tumour necrosis factor-alpha. Clin Exp Immunol 1993;92:14-18.
30. Peña AS, Crusius JBA, Koutroubakis I et al. Preliminary results on cytokine genes and mucin gene polymorphisms. Falk Symposium 85. Inflammatory Bowel Diseases. 1995, The Hague: 232-8.
31. Bach JF. Organ-specific autoimmunity. Immunology Today 1995;16:353-5.
32. Kvale D, Brandtzaeg P, Lovhang D. Up-regulation of the expression of secretory component and HLA molecules in a human colonie cell line by tumour necrosis factor-alpha and gamma-interferon. Scand J Immunol 1988;28:351-7.
33. Sturgess RP, Hooper LB, Spencer J, Hung C-H, Nelufer JM, Ciclitera PJ. Effects of interferon-gamma and tumour necrosis factor-alpha on epithelial HLA class-II expression on jejunal mucosal biopsy specimens cultured in vitro. Scand J Gastroenterol 1992;27:907-11.
34. Derckx B, Taminiau J, Radema S et al. Tumour necrosis factor antibody treatment in Crohn's disease. Lancet 1993;342:173-4.
35. Sachar DB, Andrews HA, Farmer RG et al. Proposed classification of patients subgroups in Crohn's disease. Working team report. Gastroenterol Internat 1992;5:141-54.
36. Peña AS, Meuwissen SGM. Clinical subgroups in Inflammatory Bowel Disease. In: Targan SR, Shanahan F, eds. Inflammatory Bowel Disease: from bench to bedside. Baltimore: Williams and Wilkins, 1994: 272-8.
37. Sartor RB. Insights into the pathogenesis of Inflammatory Bowel Diseases provided by new rodent models of spontaneous colitis. Inflammatory Bowel Diseases 1995;1:64-75.
38. Weyand CM, Hicok KC, Conn DL, Goronzy JJ. The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Annals of Internal Medicine 1992;117:801-6.
39. Nepom BS, Nepom GT, Mickelson E, Schaller JG, Antonelli P, Hansen JA. Specific HLA-DR4-associated histocompatibility molecules characterize patients with seropositive juvenile rheumatoid arthritis. J Clin Invest 1984;74:287-91.
40. Fronek Z, Timmerman LA, Alper CA et al. Major histocompatibility complex genes and susceptibility to systemic lupus erythematosus. Arthritis & Rheumatism 1990;33:1542-53.